Lexaria Bioscience Corp. (NASDAQ:LEXX) Financings
Financings
| Raise | Date |
|---|---|
| Common stock on exercise of existing warrants at a reduced price, with new unregistered Series A and Series B warrants Closed: US$5.9M raised · US$12.92 a share · Warrants at US$12.67 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Sep 9, 2026 |
| Registered direct offering of shares of common stock with concurrent private placement of unregistered warrants Closed: US$3.5M raised · US$1.315 a share · Warrants at US$1.19 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Advance research and development, fund working capital and general corporate purposes | Dec 16, 2025 |
| Registered direct offering of shares of common stock with concurrent private placement of unregistered warrants Closed: US$4M raised · US$1.5 a share · Warrants at US$1.37 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Sep 29, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants) Closed: US$2M raised · US$1 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: single institutional investor (2,000,000 shares of common stock) Use of proceeds: Working capital and other general corporate purposes | Apr 28, 2025 |